Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 0.75 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.64 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30557661 | 1.00 | CYP1A1 (0.75) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL30641473 | 0.88 | ALDH1A1 (0.71) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL5327111 | 0.88 | ALDH1A1 (0.71) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL23743244 | 0.86 | CYP1A1 (1.00) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL12248758 | 0.84 | ALDH1A1 (0.58) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL19627005 | 0.84 | CYP1A1 (0.75) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL18424942 | 0.83 | HSP90AA1 (0.61) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL21484609 | 0.83 | MPL (0.58) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL7228762 | 0.81 | ALDH1A1 (0.62) | CYP1A1CYP1B1MAPTNPC1RAB9A | |
| SCHEMBL19625330 | 0.81 | CYP1A1 (0.69) | CYP1A1CYP1B1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729513-A1 | A-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF | Nanjing Chempion Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025001687-A1 | Α-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF | 南京桦冠生物技术有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-117820251-B | Bis-alpha-keto acid amide compound and composition thereof | 南京桦冠生物技术有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117820251-A | Bis-alpha-keto acid amide compound and composition thereof | 南京桦冠生物技术有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116554122-B | Alpha-keto acid amide or substituted oxalic acid amide ester compound and composition thereof | 南京桦冠生物技术有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116554122-A | Alpha-keto acid amide or substituted oxalic acid amide ester compound and composition thereof | 南京桦冠生物技术有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007148113-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| WO-2002046129-A2 | INHIBITORS OF HISTONE DEACETYLASE | ABBOTT LABORATORIES (US) | 2002-06-13 | — | — | WO | disclosed |
| US-4407810-A | TREATMENT OF ALLERGIC DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| EP-0044442-A1 | N-(4-Phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound | BASF Aktiengesellschaft (DE) | 1982-01-27 | — | — | EP | disclosed |
| US-4207233-A | Azo dyes containing a thiazole component | BASF AKTIENGESELLSCHAFT (DE) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP1A1 3526/4885CYP1B1 3086/4885MAPT 2904/4885 |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | GRM1, GRM2, GRM3 | CYP1A1 3822/4885CYP1B1 4177/4885MAPT 794/4885 |
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | CYP1A1 2680/4885CYP1B1 2412/4885MAPT 1179/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP1A1 3526/4885CYP1B1 3086/4885MAPT 2904/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP1A1 3526/4885CYP1B1 3086/4885MAPT 2904/4885 |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | CYP1A1 269/4885CYP1B1 342/4885MAPT 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.